Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal ultrasound

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    286 result(s) found for: Renal ultrasound. Displaying page 6 of 15.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-003723-21 Sponsor Protocol Number: BSMO-2014-01 Start Date*: 2015-05-27
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple ne...
    Medical condition: Stage II and III triple negative breast cancer patients suitable for preoperative chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008746-20 Sponsor Protocol Number: AGO 10 Start Date*: 2010-01-28
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Randomized Phase II AGO-Study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistan...
    Medical condition: platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube, and the peritoneum
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003653-30 Sponsor Protocol Number: NS-065/NCNP-01-211 Start Date*: 2021-06-08
    Sponsor Name:NS Pharma, Inc
    Full Title: A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Con...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006310-13 Sponsor Protocol Number: CAO/ARO/AIO-12 Start Date*: 2015-01-19
    Sponsor Name:University Hospital Frankfurt, Goethe University
    Full Title: CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: A randomized phase II trial of the German Rectal Cancer Study ...
    Medical condition: Locally advanced rectal cancer (UICC stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003973-16 Sponsor Protocol Number: 2016-00601 Start Date*: 2020-11-02
    Sponsor Name:University Medical Center Groningen
    Full Title: Groningen International Study on Sentinel nodes in Vulvar cancer - III, a prospective phase 2 treatment trial
    Medical condition: vulvar cancer patients with sentinel lymph node metastases larger than 2mm
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002079-36 Sponsor Protocol Number: 73750 Start Date*: 2020-10-20
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)
    Medical condition: Esophageal squamous cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001449-42 Sponsor Protocol Number: VITDCirrhosis2012 Start Date*: 2014-10-03
    Sponsor Name:Medizinische Universität Graz, Kl. Abt. f. Endokrinoloie u. Stoffwechsel & Kl. Abt. f. Gastroenterologie u. Hepatologie
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate vitamin D supplementation on serum 25 hydroxy- vitamin D level in cirrhotic patients
    Medical condition: decompensated and compensated liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004418-17 Sponsor Protocol Number: I-BCT-1 Start Date*: 2014-05-07
    Sponsor Name:Oslo University Hospital
    Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
    Medical condition: breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001604-17 Sponsor Protocol Number: APHP220428 Start Date*: 2022-11-15
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers
    Medical condition: Patients With Acute Heart Failure and Elevated Inflammatory Markers in Emergency Department
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006647-99 Sponsor Protocol Number: 2021/ABM/01/00010 Start Date*: 2022-03-02
    Sponsor Name:Medical University of Bialystok
    Full Title: Safety Outcomes Post kidney Biopsy – randomized Clinical Evaluation of Efficacy of Desmopressin
    Medical condition: Rare and ultra-rare glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018364 Glomerulonephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003719-37 Sponsor Protocol Number: GN15CA580 Start Date*: 2017-07-25
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus (or prediabetes) and Heart Failure (SUGAR-DM-HF)
    Medical condition: Chronic heart failure with left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-007942-36 Sponsor Protocol Number: EFC6520 Start Date*: 2008-09-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major A...
    Medical condition: The subjects who will participate to this clinical trial are patients undergoing major abdominal surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) LV (Completed) EE (Completed) DK (Completed) BE (Completed) SE (Completed) HU (Completed) CZ (Completed) LT (Completed) SI (Completed) IT (Completed) SK (Completed) BG (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022656-22 Sponsor Protocol Number: A7471009 Start Date*: 2011-09-13
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) SK (Completed) PL (Completed) HU (Completed) IE (Completed) FI (Completed) BE (Completed) GB (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000684-33 Sponsor Protocol Number: OC5-DB-02 Start Date*: 2017-06-06
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004645-32 Sponsor Protocol Number: FLT190-02 Start Date*: 2020-03-24
    Sponsor Name:Freeline Therapeutics Ltd
    Full Title: A Multicentre, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012376-27 Sponsor Protocol Number: ALADIN II Start Date*: 2009-11-16
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY)
    Medical condition: Polycystic Kidney
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004243-74 Sponsor Protocol Number: CPRC2018/EVATRAN-GIRERD/JL Start Date*: 2020-06-02
    Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy
    Full Title: A randomized crossover clinical trial regarding the blockage of the mineralocorticoid receptor using Eplerenone on the evolution of arterial stiffness in kidney patients one year after transplant: ...
    Medical condition: Patients with a kidney transplantation for more than one year and on cyclosporine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000507-44 Sponsor Protocol Number: D-FR-52120-223 Start Date*: 2016-06-29
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003413-32 Sponsor Protocol Number: CRAD001A2310 Start Date*: 2006-01-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0g MMF with st...
    Medical condition: de novo heart transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002676-27 Sponsor Protocol Number: MedOPP096-MO39229 Start Date*: 2017-05-25
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 05:59:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA